hydroxychloroquine 200 mg
1 INDICATIONS AND USAGE Hydroxychloroquine sulfate tablets are an antiMalarial and antirheumatic indicated for the: Treatment of uncomplicated Malaria due to Plasmodium falciparum, Plasmodium Malariae, Plasmodium ovale, and Plasmodium vivax in adult and pediatric patients. ( 1.1 ) Prophylaxis of Malaria in geographic areas where chloroquine resistance is not reported in adult and pediatric patients. ( 1.1 ) Treatment of Rheumatoid Arthritis in adults. ( 1.2 ) Treatment of systemic Lupus erythematosus in adults. ( 1.3 ) Treatment of chronic discoid Lupus erythematosus in adults. ( 1.4 ) Limitations of Use ( 1.1 ) : Hydroxychloroquine sulfate tablets are not recommended for the: Treatment of complicated Malaria. Treatment of chloroquine or hydroxychloroquine-resistant strains of Plasmodium species. Treatment of Malaria acquired in geographic areas where chloroquine resistance occurs or when the Plasmodium species has not been identified. Prophylaxis of Malaria in geographic areas where chloroquine resistance occurs. Prevention of relapses of P. vivax or P. ovale because it is not active against the hypnozoite liver stage forms of these parasites. For radical cure of P. vivax and P. ovale infections, concomitant therapy with an 8-aminoquinoline drug is necessary. 1.1 Malaria Hydroxychloroquine sulfate tablets are indicated in adult and pediatric patients for the: Treatment of uncomplicated Malaria due to Plasmodium falciparum, Plasmodium Malariae, Plasmodium vivax, and Plasmodium ovale. Prophylaxis of Malaria in geographic areas where chloroquine resistance is not reported. Limitations of Use: Hydroxychloroquine sulfate tablets are not recommended for: Treatment of complicated Malaria. Treatment of Malaria by chloroquine or hydroxychloroquine-resistant strains of Plasmodium species [see Microbiology (12.4) ] . Treatment of Malaria acquired in geographic areas where chloroquine resistance occurs or when the Plasmodium species has not been identified. Prophylaxis of Malaria in geographic areas where chloroquine resistance occurs. Prevention of relapses of P. vivax or P. ovale because it is not active against the hypnozoite liver stage forms of these parasites. For radical cure of P. vivax and P. ovale infections, concomitant therapy with an 8-aminoquinoline drug is necessary [see Microbiology (12.4) ] . For the most current information about drug resistance, refer to the latest recommendations from the Center for Disease Control and Prevention 1 . 1.2 Rheumatoid Arthritis Hydroxychloroquine sulfate tablets are indicated for the treatment of acute and chronic Rheumatoid Arthritis in adults. 1.3 Systemic Lupus Erythematosus Hydroxychloroquine sulfate tablets are indicated for the treatment of systemic Lupus erythematosus in adults. 1.4 Chronic Discoid Lupus Erythematosus Hydroxychloroquine sulfate tablets are indicated for the treatment of chronic discoid Lupus erythematosus in adults.
aurobindo pharma limited
ROUND WHITE C
Related Pills
glipizide 10 mg
american health packaging
mirtazapine 7.5 mg
AvKARE
pepto bismol fast melts winter frost flavored bismuth subsalicylate tablet chewable
the procter & gamble manufacturing company
pepto bismol fast melts fresh berry flavored bismuth subsalicylate tablet chewable
the procter & gamble manufacturing company
Chantix First Month of Therapy Pack
Physicians Total Care, Inc.
Norco 10325 hydrocodone APAP Oral Tablet
Watson Pharma, Inc.
KlorCon 20 MEQ Extended Release Tablet
McKesson Contract Packaging
Guaifenesin 400 MG Oral Tablet
Sunrise Pharmaceutical Inc
DISCLAIMER:
"This tool does not provide medical advice, and is for informational and educational purposes only, and is not a substitute for professional medical advice, treatment or diagnosis. Call your doctor to receive medical advice. If you think you may have a medical emergency, please dial 911."
"Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service."
"This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product."
PillSync may earn a commission via links on our site
16 HOW SUPPLIED/STORAGE AND HANDLING 16.1 How Supplied Hydroxychloroquine sulfate tablets, USP are available containing 200 mg of hydroxychloroquine sulfate, USP equivalent to 155 mg of base. The 200 mg tablets are a white, film-coated, round, biconvex, beveled edge tablet debossed with “C” on one side of the tablet and plain on the other side. They are available as follows: Bottles of 100 tablets NDC 59651-889-01 Bottles of 500 tablets NDC 59651-889-05 16.2 Storage Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.] Dispense in a tight, light-resistant container as defined in the USP/NF.
More pills like ROUND C